President Donald Trump announced a phased tariff plan for imported generic drugs, which will begin with zero tariffs for two years starting August 1, 2026. Following this, a 100% tariff will be imposed from August 1, 2028, for one year, increasing to 200% from August 1, 2029. This policy aims to incentivize pharmaceutical companies to establish manufacturing facilities in the United States, a concept referred to as "reshore" production.
The news immediately impacted the stock market, particularly in India. Shares of major Indian generic drug manufacturers such as Sun Pharma, Cipla, Lupin, and Dr. Reddy's Laboratories all declined by up to 2.5%. For instance, Sun Pharma fell 2% to $1,924, Cipla declined 2.5% to $1,396, and Lupin dipped 2.5% to $2,452. Other companies like Zydus, Alkem, and Torrent Pharma also saw drops of up to 2%.
Industry experts and analysts have expressed concerns about the feasibility and consequences of these tariffs. Namit Joshi, Chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), stated that Indian drugmakers would not be able to absorb tariffs exceeding 100%, and the assumption of building a generic ecosystem in the U.S. is remote. He noted that Indian drugs account for nearly 40% of generic drugs prescribed in the U.S. and that previous tariffs had already dented exports, with projections showing a decrease from $10.5 billion in 2024-25 to $9.7 billion in 2025-26. Bharat Celly, an equity research analyst at Equirus Securities, highlighted that relocating manufacturing is a complex and lengthy process that far exceeds the two-year transition period, making it economically unviable for many products.
Critics also argue that the proposal contradicts the intent of the Hatch-Waxman framework, which aims to reduce drug prices through generic competition. Imposing such high tariffs could instead raise the cost of affordable medicines and increase the risk of supply disruptions, rather than effectively driving reshoring. While the immediate impact on exports might be limited due to the deferred implementation, the proposed tariffs could significantly alter the economics of supplying the U.S. market and are seen by some as a negotiating tactic set beyond the next U.S. election cycle.
